Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2005
11/09/2005CN1694726A Mucolytic and anti-elastase compounds and methods of use thereof
11/09/2005CN1694717A Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
11/09/2005CN1694711A A method of extending the dose range of vitamin d compounds
11/09/2005CN1694707A Pde-v inhibitor and medicine composite with active agent
11/09/2005CN1694700A Non-nucleoside reverse transcriptase inhibitors
11/09/2005CN1694695A Novel nutraceutical compositions comprising epigallocatechin gallate
11/09/2005CN1694690A Combination chemotherapy compositions and methods
11/09/2005CN1692940A External-applied ointment used for treating thyropathy, and its prepn. method
11/09/2005CN1226332C Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug
11/09/2005CN1226304C Methylene steroids as novel androgens
11/09/2005CN1226036C New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962988 Comprises deiminase polypeptide for sterilization of female animals and/or the generation of antibodies useful for temporary, reversible contraception
11/08/2005US6962976 Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and niluzole
11/08/2005US6962940 Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders
11/08/2005US6962936 Treating diseases such as cancer, inflammatory disorders, restenosis,
11/08/2005US6962931 Oral bioavailability of a CETP inhibitor
11/08/2005US6962926 monocyte chemoattractant protein-1 (MCP-1); 1-{1,3-dimethyl-6-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazolo[3,4-b]pyridine-5-carbonyl}-3-(3-isopropoxyphenyl)urea; inflammatory/autoimmune diseases (multiple sclerosis), and allergic hypersensitivity
11/08/2005US6962908 Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
11/08/2005US6962900 Pharmaceutical being used for treating HIV infection, the composition and uses thereof
11/08/2005US6962799 Microtubule-associated proteins and tubulins
11/08/2005US6962792 cyclin-dependent kinase 4 (CDK4); useful in treatment of tumours and other hyperproliferative disorders
11/08/2005US6962712 Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent
11/08/2005US6962698 providing expanded populations of stem cells, as well as progenitor cells, which can be used for hematopoietic cell transplantations, or generation of stem or progenitor cells suitable for genetic manipulations, which may be used for gene therapy
11/08/2005US6962696 Compositions and methods for tumor-targeted delivery of effector molecules
11/08/2005US6962694 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
11/08/2005US6962691 Topical spray compositions
11/08/2005CA2269501C Pellets having a core coated with an antifungal and a polymer
11/08/2005CA2251690C New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
11/06/2005CA2504403A1 Prognostic for hematological malignancy
11/03/2005WO2005103291A1 Novel ligand of g-protein-conjugated receptor protein and use thereof
11/03/2005WO2005103283A1 Novel method of screening
11/03/2005WO2005103257A1 GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA
11/03/2005WO2005103256A1 Gene encoding gtpase activating protein and gene product thereof
11/03/2005WO2005103081A2 Human monoclonal antibodies against cd20
11/03/2005WO2005103077A1 Recombinant polypeptides of the members of the tnf ligand family and use thereof
11/03/2005WO2005102392A2 Combinations for treating hiv infection
11/03/2005WO2005102391A1 Combinations for the treatment of aids or hiv infections
11/03/2005WO2005102390A2 Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
11/03/2005WO2005102389A2 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
11/03/2005WO2005102388A1 Novel blt2-mediated disease, and blt2 binding agent and compound
11/03/2005WO2005102386A1 Treatment of fungal infections
11/03/2005WO2005102381A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth
11/03/2005WO2005102366A2 Lithium combinations, and uses related thereto
11/03/2005WO2005102364A1 Compressed pharmaceutical compositions comprising peg and electrolytes
11/03/2005WO2005102351A1 Composition comprising a diuretic and/or cardiac glycoside for the treatment of dna viral infections of the eye
11/03/2005WO2005102344A1 Pharmaceutical composition
11/03/2005WO2005102342A1 New pharmaceutical compositions for the treatment of sexual disorders ii
11/03/2005WO2005102321A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
11/03/2005WO2005102317A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
11/03/2005WO2005102300A1 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS
11/03/2005WO2005102296A2 Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
11/03/2005WO2005102295A1 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
11/03/2005WO2005102275A2 Galantamine salts, method of producing it and nasal composition thereof
11/03/2005WO2005089762A3 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
11/03/2005WO2005089742A8 Medicine for prevention or treatment of frequent urination or urinary incontinence
11/03/2005WO2005079772A3 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
11/03/2005WO2005067921A8 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof
11/03/2005WO2005050215A8 Selection of lactic acid bacteria enhancing the immune response against streptococcus pneumoniae
11/03/2005WO2005027972A3 Combination of a vegf receptor inhibitor with a chemotherapeutic agent
11/03/2005WO2005002555A3 Sirt1 modulators for manipulating cell/organism lifespan/stress response
11/03/2005WO2004096131A3 Inhibitors of akt activity
11/03/2005WO2004089355A8 Compositions for treating microbial and parasitic infections in cattle and other animals
11/03/2005WO2003068168A3 Helical peptidomimetics and use b-amyloid-associated diseases
11/03/2005WO2002004440A9 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
11/03/2005US20050245735 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same
11/03/2005US20050245617 Methods and compositions for the treatment of CNS-related conditions
11/03/2005US20050245613 Use of gaba-b receptor positive modulators in gastro-intestinal disorders
11/03/2005US20050245595 Positive modulators of nicotinic receptor agonists
11/03/2005US20050245587 Treatment of dyskinesia
11/03/2005US20050245570 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
11/03/2005US20050245564 Methods and compositions related to IRM compounds and toll-like receptor pathways
11/03/2005US20050245563 Chk-1 inhibitors
11/03/2005US20050245557 Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
11/03/2005US20050245553 Amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl chloromethanesulfonate; cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system
11/03/2005US20050245549 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
11/03/2005US20050245545 administering a xanthine derivative such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11/03/2005US20050245543 Histamine-3 receptor antagonists
11/03/2005US20050245539 Female sexual disorders; combination therapy
11/03/2005US20050245525 Compounds useful for inhibiting CHK1
11/03/2005US20050245509 Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
11/03/2005US20050245499 Heterocyclic protein kinase inhibitors and uses thereof
11/03/2005US20050245493 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
11/03/2005US20050245488 Pharmaceutically active compounds and methods of use thereof
11/03/2005US20050245486 Prostate specific membrane antigen (PSMA); for diagnosis, detection and treatment of cancer; gene overexpression; kits
11/03/2005US20050245471 Combination products for use in antitumoral treatment
11/03/2005US20050245467 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
11/03/2005US20050245466 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
11/03/2005US20050245462 Treatment of cancer with 2-deoxyglucose
11/03/2005US20050245440 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
11/03/2005US20050244915 Assays for modulators of asparaginyl hydroxylase
11/03/2005US20050244896 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
11/03/2005US20050244894 Modulators of paraptosis and related methods
11/03/2005US20050244888 Antibodies to human chemokine beta-9
11/03/2005US20050244859 Cell based assay
11/03/2005US20050244826 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen and/or wnt
11/03/2005US20050244817 Mammalian genes involved in viral infection and tumor suppression
11/03/2005US20050244524 Blood sugar regulating product from soybean seeds
11/03/2005US20050244523 Topical anti-cancer compositions and methods of use thereof
11/03/2005US20050244511 Adding an EDTA/NaOH mixture to acontainer and subsequently adding at least one metal compound; adding Na2SeO3 to the container to obtain the trace element solution; improve the trace mineral status of an animal
1 ... 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 ... 1151